Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Tom Brady's playful rivalry with Eli Manning reignited after a viral video showed Brady joking about never losing to Manning, referencing their Super Bowl clashes. Giants fans swiftly responded ...

Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes management results when compared to the pill’s injectable counterparts. About 1 in 8 adults in the U.S. has taken ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

The India launch of Eli Lilly’s popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

And Lilly just took a major step in the right direction. Did Eli Lilly just say checkmate to Novo Nordisk? Let's find out. So, first a quick bit about how this class of drugs works. Novo Nordisk's ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), on Friday declined to endorse Kisunla (donanemab), Eli Lilly’s (NYSE:LLY) candidate for early Alzheimer’s disease ...

You can reach Allison on Signal at AllisonDeAngelis.01. European Medicines Agency advisers said Friday that Eli Lilly’s Alzheimer’s disease treatment should not be approved, once again ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...